Biofilm formation by Stenotrophomonas maltophilia:: Modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime

被引:136
|
作者
Di Bonaventura, G
Spedicato, A
D'Antonio, D
Robuffo, I
Piccolomini, R
机构
[1] Univ G DAnnunzio, Ctr Sci Invecchiamento, Lab 27, I-66100 Chieti, Italy
[2] Univ G DAnnunzio, Dipartimento Sci Biomed, Lab Microbiol Clin, I-66100 Chieti, Italy
[3] Univ G DAnnunzio, Ctr Sci Invecchiamento, I-66100 Chieti, Italy
[4] CNR, Ist Trapianti Organo & Immunocitol, Sez Chieti, Chieti, Italy
[5] ASL, Serv Microbiol Clin, Dipartimento Ematol & Oncol, Osped Spirito Santo, Pescara, Italy
关键词
D O I
10.1128/AAC.48.1.151-160.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We investigated the in vitro effects of seven fluoroquinolones (ciprofloxacin, grepafloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and rufloxacin), compared to those of trimethoprim-sulfamethoxazole (SXT) and ceftazidime on total biomass and cell viability of Stenotrophomonas maltophilia biofilm. S. maltophilia attached rapidly to polystyrene, within 2 h of incubation, and then biofilm formation increased over time, reaching maximum growth at 24 h. In the presence of fluoroquinolones at one-half and one-fourth the MIC, biofilm biomass was significantly (P < 0.01) reduced to 55 to 70% and 66 to 76% of original mass, respectively. Ceftazidime and SXT did not exert any activity. Biofilm bacterial viability was significantly reduced by all antibiotics tested at one-half the MIC. At one-fourth the MIC all antibiotics, except levofloxacin, significantly reduced viability. Treatment of preformed biofilms with bactericidal concentrations (500, 100, and 50 mu g/ml) of all fluoroquinolones caused, except for norfloxacin, significant reduction of biofilm biomass to 29.5 to 78.8, 64.1 to 83.6, and 70.5 to 82.8% of original mass, respectively. SXT exerted significant activity at 500 mu g/ml only. Ceftazidime was completely inactive. Rufloxacin exhibited the highest activity on preformed biofilm viability, significantly decreasing viable counts by 0.6, 5.4, and 17.1% at 500, 100, and 50 mu g/ml, respectively. Our results show that (i) subinhibitory (one-half and one-fourth the MIC) concentrations of fluoroquinolones inhibit adherence of S. maltophilia to polystyrene and (ii) clinically achievable concentrations (50 and 100 mu g/ml) of rufloxacin are able to eradicate preformed S. maltophilia biofilm.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 50 条
  • [1] Biofilm Eradication of Stenotrophomonas maltophilia by Levofloxacin and Trimethoprim-Sulfamethoxazole
    Del Rio-Chacon, Jose Mauricio
    Rojas-Larios, Fabian
    Bocanegra-Ibarias, Paola
    Salas-Trevino, Daniel
    Espinoza-Gomez, Francisco
    Camacho-Ortiz, Adrian
    Flores-Trevino, Samantha
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2024, 77 (04) : 213 - 219
  • [2] Trimethoprim-sulfamethoxazole in the treatment of Stenotrophomonas maltophilia osteomyelitis
    Landrum, ML
    Conger, NG
    Forgione, MA
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (10) : 1551 - 1552
  • [3] Temperature, pH and Trimethoprim-Sulfamethoxazole Are Potent Inhibitors of Biofilm Formation by Stenotrophomonas maltophilia Clinical Isolates
    Biocanin, Marjan
    Madi, Haowa
    Vasiljevic, Zorica
    Kojic, Milan
    Jovcic, Branko
    Lozo, Jelena
    POLISH JOURNAL OF MICROBIOLOGY, 2017, 66 (04) : 433 - 438
  • [4] Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: An increasing problem
    Al-Jasser A.M.
    Annals of Clinical Microbiology and Antimicrobials, 5 (1)
  • [5] Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim-sulfamethoxazole resistance
    Neela, Vasanthakumari
    Rankouhi, Seyedeh Zahra Rouhani
    van Belkum, Alex
    Goering, Richard V.
    Awang, Rukman
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 (08) : E603 - E607
  • [6] Osteomyelitis due to Stenotrophomonas maltophilia treated with trimethoprim-sulfamethoxazole monotherapy
    Osakwe, Nonso
    IDCASES, 2023, 32
  • [7] STENOTROPHOMONAS MALTOPHILIA TRIMETHOPRIM-SULFAMETHOXAZOLE RESISTANCE IN A CRITICALLY ILL POPULATION
    Magrum, BrookeAnne
    Elefritz, Jessica
    Hanks, Christine
    Murphy, Claire
    Stevenson, Kurt
    CRITICAL CARE MEDICINE, 2020, 48
  • [8] Monotherapy with Fluoroquinolone or Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Infections
    Wang, Yu Lin
    Scipione, Marco R.
    Dubrovskaya, Yanina
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 176 - 182
  • [9] The Efflux Pump SmeDEF Contributes to Trimethoprim-Sulfamethoxazole Resistance in Stenotrophomonas maltophilia
    Blanca Sanchez, Maria
    Luis Martinez, Jose
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) : 4347 - 4348
  • [10] Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia
    Graves, Emily T.
    Wardlow, Lynn
    Ogake, Stella
    Bazan, Jose A.
    Coe, Kelci
    Kuntz, Kaitlyn
    Elefritz, Jessica L.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2025,